Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran.
Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Sci Rep. 2023 Nov 18;13(1):20213. doi: 10.1038/s41598-023-47611-w.
Several vaccines have been developed against SARS-CoV-2 and subsequently approved by national/international regulators. Detecting specific antibodies after vaccination enables us to evaluate the vaccine's effectiveness. We conducted a prospective longitudinal study among members of Tarbiat Modares University of Tehran, Iran, from 4 September 2021 until 29 December 2021. We aimed to compare the humoral immunogenicity of 3 vaccine types. Participants consisted of 462 adults. Anti-SARS-CoV-2 receptor-binding domain [RBD] IgG titer was compared in 3 groups, each vaccinated by available vaccines in Iran at the time: Oxford/AstraZeneca, COVIran Barekat, and Sinopharm. The median IgG titer was: 91.2, 105.6, 224.0 BAU/ml for Sinopharm, COVIran Barekat and Oxford/AstraZeneca respectively after the first dose; 195.2, 192.0, 337.6 BAU/ml after the second one. We also analyzed the frequency of antibody presence in each vaccine group, in the same order the results were 59.0%, 62.6% and 89.4% after the first dose and 92.1%,89.5% and 98.9% after the second. The comparison of results demonstrated that AstraZeneca vaccine is a superior candidate vaccine for COVID-19 vaccination out of the three. Our data also demonstrated statistically significant higher antibody titer among recipients with an infection history.
几种针对 SARS-CoV-2 的疫苗已被开发并随后获得国家/国际监管机构的批准。接种疫苗后检测特定抗体可评估疫苗的有效性。我们在伊朗德黑兰塔比亚特莫达雷斯大学的成员中进行了一项前瞻性纵向研究，时间为 2021 年 9 月 4 日至 2021 年 12 月 29 日。我们旨在比较 3 种疫苗类型的体液免疫原性。参与者包括 462 名成年人。比较了 3 组抗 SARS-CoV-2 受体结合域 [RBD] IgG 滴度，每组均接种了当时伊朗可用的疫苗：牛津/阿斯利康、COVIran Barekat 和科兴。首次接种后，Sinopharm、COVIran Barekat 和 Oxford/AstraZeneca 的 IgG 滴度中位数分别为 91.2、105.6 和 224.0 BAU/ml；第二次接种后分别为 195.2、192.0 和 337.6 BAU/ml。我们还分析了每种疫苗组中抗体存在的频率，结果按顺序分别为首次接种后 59.0%、62.6%和 89.4%，第二次接种后为 92.1%、89.5%和 98.9%。结果比较表明，在这 3 种疫苗中，阿斯利康疫苗是 COVID-19 疫苗的首选候选疫苗。我们的数据还表明，有感染史的接种者的抗体滴度显著更高。
